Watch GRCE. Know when insiders buy.
One email the day a filing lands. Free.
GRCE
Grace Therapeutics, Inc.
2.26
+0.12 +5.61%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
58
WATCH · insiders 71, shorts 45
Insiders, 90 days
+$246K
net buying · 3 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $47.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$20.2MNET CASH —52W 2.07 – 5.13SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | — | — | — | −$15.9M | −$15.8M | — | -0.91 | −$3.2M | — | — | Aug 13 |
| Q4 2026 · Mar 31derived | — | — | — | −$3M | −$1.2M | −285.2% | -0.06 | −$1.7M | — | — | Jun 18 |
| Q3 2026 · Dec 31 | — | — | — | −$2.4M | −$2.3M | — | -0.14 | −$2.2M | — | — | Feb 12 |
| Q2 2026 · Sep 30 | — | — | — | −$2.5M | −$938K | — | -0.06 | −$3.1M | — | — | Feb 12 |
| Q1 2026 · Jun 30 | — | — | — | −$3.1M | −$3.4M | — | -0.21 | −$1.8M | — | — | Aug 13 |
| Q4 2025 · Mar 31derived | — | — | — | −$3.2M | $636K | — | 0.10 | −$3M | — | — | Jun 18 |
| Q3 2025 · Dec 31 | — | — | — | −$3.7M | −$4.2M | — | -0.36 | −$4.1M | — | — | Feb 12 |
| Q2 2025 · Sep 30 | — | — | — | −$4.8M | −$3.4M | — | -0.30 | −$4.2M | — | — | Feb 12 |
| Q1 2025 · Jun 30 | — | — | — | −$5M | −$2.6M | — | -0.24 | −$3.6M | — | — | Feb 12 |
| Q4 2024 · Mar 31derived | — | — | — | −$3.3M | −$3.2M | — | -0.26 | −$2.1M | — | — | Jun 23 |
| Q3 2024 · Dec 31 | — | — | — | −$3M | −$2.4M | — | -0.21 | −$1.9M | — | — | Feb 13 |
| Q2 2024 · Sep 30 | — | — | — | −$2.1M | −$3.3M | — | -0.43 | −$2.1M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | — | — | −$11.1M | −$7.8M | — | -0.47 | −$8.9M | — | — | — | — |
| FY2025 · to Mar 31 | — | — | −$16.7M | −$9.6M | — | -0.79 | −$14.9M | — | — | — | — |
| FY2024 · to Mar 31 | — | — | −$12.9M | −$12.9M | — | -1.35 | −$12.3M | — | — | — | — |
| FY2023 · to Mar 31 | — | — | −$52.2M | −$42.4M | — | -5.71 | −$15.9M | — | — | — | — |
| FY2022 · to Mar 31 | $100M | 100.0% | −$15.6M | −$9.8M | -9.8% | -0.27 | −$17.2M | — | — | — | — |
| FY2021 · to Mar 31 | — | — | −$16.4M | −$19.7M | — | -1.33 | −$14.3M | — | — | — | — |
Every number comes from Grace Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.